JFG
RARE icon

Jefferies Financial Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jefferies Financial Group’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$324K Sell
15,488
-461,604
-97% -$10.4M ﹤0.01% 1355
2025
Q4 		$11M Buy
+477,092
New +$15.7M 0.06% 300
2024
Q3 		– Sell
-10,250
Closed -$421K – 1710
2024
Q2 		$421K Buy
+10,250
New +$438K ﹤0.01% 1016

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Jefferies Financial Group's RARE Position: Q1 2026 in Review

Jefferies Financial Group reduced its Ultragenyx Pharmaceutical (RARE) stake by 97% in Q1 2026, selling an estimated $10.4M and leaving 15,488 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #1355.

Jefferies Financial Group first reported a position in RARE in Q2 2024 and has held it in 3 quarters since. The position peaked at $11M in Q4 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Jefferies Financial Group held 15,488 shares of Ultragenyx Pharmaceutical worth $324K as of Q1 2026.
  • Jefferies Financial Group sold 461,604 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $10.4M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1355 holding.
  • Jefferies Financial Group first reported a position in Ultragenyx Pharmaceutical in Q2 2024 and has held it in 3 quarters since.
  • Jefferies Financial Group's Ultragenyx Pharmaceutical position peaked at $11M in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.